ASP3291

DRUG2 trials

Sponsors

Telsar Pharma Inc.

Conditions

Ulcerative Colitis

Phase 1

A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

CompletedNCT01320332

Telsar Pharma Inc.Ulcerative Colitis

Start: 2010-08-31End: 2011-08-31Updated: 2012-07-24

Phase 2

Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis

CompletedNCT01612039

Telsar Pharma Inc.Ulcerative Colitis

Start: 2012-07-31End: 2014-04-30Updated: 2016-09-28